Apollomics, Inc. (NASDAQ:APLM) Short Interest Update

Apollomics, Inc. (NASDAQ:APLM) saw a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 10,800 shares, a decrease of 50.5% from the December 15th total of 21,800 shares. Based on an average daily volume of 309,200 shares, the short-interest ratio is presently 0.0 days. Currently, 1.6% of the company’s shares are sold short.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Apollomics stock. Exchange Traded Concepts LLC lifted its position in Apollomics, Inc. (NASDAQ:APLM) by 247.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,259,117 shares of the company’s stock after acquiring an additional 896,316 shares during the period. Exchange Traded Concepts LLC owned approximately 1.41% of Apollomics worth $179,000 at the end of the most recent quarter. 19.13% of the stock is owned by hedge funds and other institutional investors.

Apollomics Stock Performance

Apollomics stock traded up $0.11 during trading hours on Wednesday, reaching $10.23. 204 shares of the company’s stock traded hands, compared to its average volume of 25,152. Apollomics has a fifty-two week low of $6.50 and a fifty-two week high of $105.00. The firm’s 50 day moving average is $10.29 and its 200-day moving average is $13.55.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.